Paliperidone Sandoz (Paliperidone Palmitate)

Paliperidone Palmitate, the active ingredient in Paliperidone Sandoz, is a long‑acting atypical antipsychotic presented as a depot injection for intramuscular use. It is indicated for the treatment of schizophrenia in adult patients. GNH USA supplies Paliperidone Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Paliperidone Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Paliperidone Sandoz is an atypical antipsychotic used in the management of schizophrenia and related psychotic disorders. - Schizophrenia: Reduces the frequency and severity of psychotic episodes and helps maintain long‑term symptom control. - Schizoaffective disorder: Alleviates both mood and psychotic symptoms when prescribed as part of a comprehensive treatment plan. - Maintenance therapy after acute stabilization: Provides sustained drug levels to prevent relapse following successful acute phase treatment.

Paliperidone Sandoz may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Injection site pain: localized discomfort at the administration site. - Weight gain: gradual increase in body weight. - Sedation: drowsiness or reduced alertness. - Constipation: reduced bowel motility. - Dry mouth: decreased salivation.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: rare but potentially life‑threatening reaction. - Tardive dyskinesia: persistent involuntary movements. - Hyperglycaemia: elevated blood glucose levels. - Orthostatic hypotension: marked drop in blood pressure upon standing. - Seizures: rare occurrence, especially in predisposed individuals.

When prescribing Paliperidone Sandoz, clinicians should consider several safety aspects. - Cardiovascular monitoring: assess for QT prolongation and orthostatic hypotension. - Metabolic screening: regularly check blood glucose and lipid profiles. - Pregnancy and lactation: evaluate risk‑benefit ratio before use. - Elderly patients: start at lower doses and monitor for sedation and falls. - Drug‑interaction review: assess concomitant medications for additive CNS effects. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Paliperidone Sandoz can interact with several drug classes, requiring clinical vigilance.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase paliperidone exposure and risk of toxicity. - QT‑prolonging agents: additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): may enhance sedation. - Antihypertensives: potential for additive orthostatic effects. - Antidiabetic drugs: may require dose adjustment due to metabolic changes.